Sanofi's IMROZ Phase 3 Study Shows Sarclisa With VRd Reduces Risk Of Disease Progression Or Death By 40% In Newly Diagnosed Transplant-Ineligible Multiple Myeloma; First Global Phase 3 Study Of Anti-CD38 With VRd To Improve PFS And Show Deep...
Sanofi's IMROZ Phase 3 Study Shows Sarclisa With VRd Reduces Risk Of Disease Progression Or Death By 40% In Newly Diagnosed Transplant-Ineligible Multiple Myeloma; First Global Phase 3 Study Of Anti-CD38 With VRd To Improve PFS And Show Deep...
賽諾菲安萬特的IMROZ第3期研究顯示Sarclisa與VRd聯用，可將新診斷的無法移植多發性骨髓瘤患者的疾病進展或死亡風險降低40％，這是全球首個用VRd聯合抗CD38的第3期研究，以改善PFS並顯示深度。
Sanofi's IMROZ Phase 3 Study Shows Sarclisa With VRd Reduces Risk Of Disease Progression Or Death By 40% In Newly Diagnosed Transplant-Ineligible Multiple Myeloma; First Global Phase 3 Study Of Anti-CD38 With VRd To Improve PFS And Show Deep Responses; Results Presented At ASCO And Published In NEJM
賽諾菲安萬特的IMROZ第三期研究表明，與VRd聯用的Sarclisa減少了新診斷的不能接受移植的多發性骨髓瘤患者疾病進展或死亡的風險40％；此爲首個全球Phasse 3研究，研究抗CD38與VRd聯用在改善患者無進展生存期和展現深度反應方面的結果；研究結果在ASCO上公佈並發表在NEJM上。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。